Acasti Announces Closing Of CAD$2.15 Million Private Placement

LAVAL, Quebec, Feb. 7, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti" or the " Corporation") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announced today the closing of a private placement of CAD$2,150,000 of units of Acasti (" Units") at a price of CAD$1.33 per Unit, each Unit consisting of one (1) Class A share (" Common Share") and one (1) Common Share purchase warrant (" Warrant") of Acasti (the " Private Placement"). Each Warrant will entitle the holder to purchase one Common Share (" Warrant Share") at an exercise price of CAD$1.60 per Warrant Share, subject to adjustment, at any time until 5:00 p.m. (Montreal time) on December 3, 2018.

The Units were all issued to The Fiera Capital QSSP II Investment Fund Inc. (the " Fund") under the Quebec Stock Savings Plan II (the " QSSP II"), and could not be qualified under the QSSP II and subscribed for by the Fund under Acasti's public offering completed on December 3, 2013 (the " Public Offering"), due to particular requirements of the QSSP II. Except for the qualification of the shares issued to the Fund under the QSSP II, the terms of the Units issued under the Private Placement are substantially the same as those of the units issued as part of the Public Offering.

"Fiera Capital had previously manifested its interest in participating in the Public Offering deal, but was not able to subscribe for units due to QSSP II eligibility requirements," stated Xavier Harland, Chief Financial Officer at Acasti. "We are pleased to complete this financing with Fiera Capital, bringing our total gross equity raised proceeds, including those from the Public Offering, to approximately US$25M," he added.

If you liked this article you might like

These 5 Stocks Under $10 Could Make You a Lot of Money

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar: Venaxis, McDermott and More

Why Acasti Pharmaceuticals (ACST) Stock Is Up Today

4 Stocks Under $10 to Trade for Breakouts